Pfizer's Strategic Partnerships Boost Tissue Transglutaminase Test Market Growth Globally
The Tissue Transglutaminase Test, also known as gluten sensitivity testing, plays a crucial role in diagnosing various gluten-related disorders, including celiac disease. This test detects antibodies produced by the body in response to gluten ingestion, aiding in the accurate identification of gluten sensitivity and its associated complications. By measuring levels of tissue transglutaminase (tTG) antibodies, healthcare professionals can assess the severity of gluten sensitivity and tailor appropriate treatment plans for affected individuals. Gluten sensitivity testing has become indispensable in clinical practice, facilitating early diagnosis and management of celiac disease to improve patient outcomes and quality of life.
Tissue Transglutaminase Test Market Size was valued at USD 4.46 Billion in 2023. The Global Tissue Transglutaminase Test industry is projected to grow from USD 5.30 Billion in 2024 to USD 21.19 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.98% during the forecast period (2024 - 2032).
Regional Analysis
- The Americas:
- Significant market share due to extensive medication use and high healthcare expenditure
- Fast uptake of new technology in the US drives global tTG testing market
- Concentration of major research companies and organizations boosts market growth
- Europe:
- Second largest market globally due to high income and healthcare penetration
- Asia Pacific:
- Expected rapid growth, with China and India leading due to fast-growing healthcare sector
- Middle East & Africa:
- Gulf nations like Saudi Arabia and the UAE are driving the market
- Africa witnessing moderate growth due to poor economic and political conditions and healthcare development
Segmentation
The global tissue transglutaminase testing market is segmented based on types and end users.
- Types:
- Serological
- Biopsy testing
- Others
- Serological testing sub-segmented into:
- Tissue transglutaminase (tTG) antibody- IgA, serum
- Tissue transglutaminase (tTG) antibody- IgG, serum
- Serological testing sub-segmented into:
- End Users:
- Hospitals & clinics
- Homecare
- Research organizations
- Others
Celiac disease diagnosis heavily relies on serological tests such as the Tissue Transglutaminase Test, also referred to as celiac disease testing. This diagnostic tool detects antibodies, particularly tissue transglutaminase (tTG) antibodies, which are indicative of gluten intolerance and potential damage to the small intestine. By accurately identifying individuals with celiac disease, healthcare providers can initiate timely interventions, including dietary modifications and lifestyle adjustments, to alleviate symptoms and prevent long-term complications. Gluten sensitivity testing is instrumental in enhancing the diagnostic process and ensuring appropriate management strategies for individuals with gluten-related disorders.
Global Tissue Transglutaminase Test Market –Competitive Landscape
The well-established market players are involved in strategic collaborations and new product launches to gain an edge over other competitors in this market.
Some of the Tissue Transglutaminase Test companies are Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, Zedira GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Amgen Inc., Ajinomoto Co, Inc., Yiming Biological Products Co., Ltd., Micro-Tech Foods Ingredients, Inc, Kinry Food Ingredients Co., Ltd., Nanning Pangbo Biological Engineering Co., Ltd. and BioRap Technologies Ltd.
For more information visit at MarketResearchFuture
Other Trending Reports
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian